Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Industry experts said profit pressure and M&A contributed to job losses. They said layoffs will likely persist in 2025, but ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

In the business of drug development, deals can be just as important as scientific breakthroughs. Many of today's most lucrative medicines, from the life-saving cancer treatment Keytruda to the ...

Regeneron Pharmaceuticals intends to advance two blood-thinning drugs into Phase 3 testing next year after mid-stage study results showed they matched or surpassed marketed medicines at preventing ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.

AbbVie will pay $200 million to acquire privately held Nimble Therapeutics and its pipeline of oral peptide drugs for immune diseases like psoriasis and inflammatory bowel disease, the pharmaceutical ...